Plasmodium Falciparum Malaria Clinical Trial
Official title:
A Phase I/IIa Sporozoite Challenge Study to Assess the Protective Efficacy of Two Prime-Boost Malaria Vaccine Candidates: ChAd63 and MVA Encoding ME-TRAP and the Same Viral Vectors Encoding CS
This study aims to assess the safety and effectiveness of four new candidate malaria
vaccines; ChAd63 CS, ChAd63 ME-TRAP, MVA CS & MVA ME-TRAP. These vaccines consist of viruses
(ChAd63 and MVA) which have been genetically modified so (i) they cannot replicate in humans
and (ii) they include parts of the malaria parasite; Plasmodium falciparum (CS and ME-TRAP).
The hope is that these vaccines will induce immune responses in vaccinees that are able to
prevent malaria.
This proposed study will compare how effective ChAd63-MVA CS is at preventing malaria
infection in UK volunteers following malaria challenge compared to ChAd63-MVA ME-TRAP.
The study will be conducted at the University of Oxford's Centre for Clinical Vaccinology
and Tropical Medicine (CCVTM), Oxford, UK and the Wellcome Trust Clinical Research Facility
in Southampton, UK. The malaria challenge will take place at the insectary at Imperial
College (Infection and Immunity Section) in London, UK.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04577066 -
Safety and Preliminary Protective Efficacy of Genetically Attenuated GA2 Parasites.
|
Phase 1/Phase 2 | |
| Completed |
NCT01883609 -
A Safety and Efficacy Study of ChAd63/MVA METRAP + RTS,S
|
Phase 1/Phase 2 | |
| Completed |
NCT00593398 -
Malarial Immunity in Pregnant Cameroonian Women
|
||
| Completed |
NCT01659281 -
Efficacy of Artesunate-Mefloquine Combination Therapy in Trat Province, Thailand
|
N/A | |
| Completed |
NCT00074841 -
Trial of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine for the Treatment of Uncomplicated Malaria in India
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04416945 -
Targeting High Risk Populations With Enhanced Reactive Case Detection in Southern Lao Peoples Democratic Republic
|
N/A | |
| Completed |
NCT00314899 -
Fetal Immunity to Falciparum Malaria
|
||
| Completed |
NCT02867059 -
SJ733 Induced Blood Stage Malaria Challenge Study
|
Phase 1 | |
| Completed |
NCT00701961 -
Pharmacokinetic of Mefloquine-Artesunate in Plasmodium Falciparum Malaria Infection in Pregnancy
|
Phase 2/Phase 3 | |
| Completed |
NCT00707200 -
The Cytoadherence in Pediatric Malaria (CPM) Study
|
N/A | |
| Completed |
NCT00338520 -
Hyperphenylalaninemia in Cerebral Malaria
|
N/A | |
| Completed |
NCT00393757 -
Malaria Transmission and Immunity in Highland Kenya
|
||
| Completed |
NCT03783299 -
Targeted Active Case Detection Among High Risk Populations in Southern Lao Peoples Democratic Republic
|
Phase 4 | |
| Completed |
NCT02614404 -
Effect of Imatinib on Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria
|
Phase 1 | |
| Completed |
NCT00358332 -
Phase I Pediatric FMP2.1/AS02A Trial in Mali
|
Phase 1 | |
| Completed |
NCT00730782 -
Assessment of Three Formulations of the Candidate Vaccine AMA 1 in Healthy Dutch Adult Volunteers
|
Phase 1 | |
| Completed |
NCT00349713 -
FMP2.1 Trial in Bandiagara, Mali
|
Phase 1 | |
| Recruiting |
NCT05052502 -
Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand
|
N/A | |
| Completed |
NCT04093765 -
Mass Screening and Treatment for Reduction of Falciparum Malaria
|
N/A | |
| Completed |
NCT03764527 -
Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate + Amodiaquine in Zanzibar
|
Phase 4 |